Product Details
| Alternative Name: | Matrix metalloproteinase 14, Membrane type matrix metalloproteinase 1, MT-1 MMP |
| |
| MW: | 22.5 kDa |
| |
| Source: | Produced in E.coli. Active Matrix Metalloproteinase-14 (MMP-14, Membrane-Type Matrix Metalloproteinase 1, MT1-MMP) catalytic domain from human cDNA. The enzyme consists of the catalytic domain of human MMP-14 (Tyr112-Arg298, NM_004995) with a C-terminal purification tag. This represents a naturally-occurring active form of MMP-14 which lacks the C-terminal hemopexin domain. MMPs lacking this domain cannot cleave native collagens; however, activity toward other targets such as gelatin, casein, or peptide substrates is unaffected. |
| |
| UniProt ID: | P50281 |
| |
| Formulation: | Liquid. In 50mM TRIS, pH 7.5, containing 5mM calcium chloride, 300mM sodium chloride, 20µM zinc chloride, 0.5% Brij-35, and 30% glycerol. |
| |
| Purity Detail: | Partially purified by single-step affinity chromatography and gel filtration. |
| |
| Activity: | Preincubation of MMP-14 catalytic domain at 13.6nM with the broad-spectrum inhibitor GM6001 (Prod. No. BML-EI300) at 20nM for 1 hour completely inhibits enzymatic activity. |
| |
| Specific Activity: | ≥3000 pmol/min/µg at 37°C using the colorimetric thiopeptolide Ac-Pro-Leu-Gly-S-Leu-Leu-Gly-OEt (100 µM; Prod. No. BML-P125) as substrate. |
| |
| Application Notes: | Useful tool to study enzyme kinetics, cleave target substrates, and screen for inhibitors. |
| |
| Shipping: | Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Use/Stability: | The enzyme is stable on ice for at least several hours. However, it is recommended that thawing and dilution of the enzyme be done within as short a time as possible before start of the assay. NOTE: When stored at -70°C, this enzyme is stable at the concentration supplied, in its current storage buffer. Procedures such as dilution of the enzyme followed by refreezing could lead to loss of activity. |
| |
| Handling: | After opening, prepare aliquots and store at -70°C. Avoid freeze/thaw cycles. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity: C.C. Clement, et al.; J. Biol. Chem.
291, 5576 (2016),
Abstract;
Full Text
MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development: G. Jin, et al.; EMBO J.
30, 2281 (2011),
Abstract;
Full Text
Regulation of ATPase activity of transglutaminase 2 by MT1-MMP: implications for mineralization of MC3T3-E1 osteoblast cultures: Y. Nakano, et al.; J. Cell. Physiol.
223, 260 (2010),
Abstract;
The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways: T. Miki, et al.; J. Biol. Chem.
282, 12341 (2007),
Abstract;
Full Text
Related Products
